<===
The survival and cardiovascular benefits of phosphate binders Renagel and Renvela are bolstering sales, and Genzyme recently claimed more than a 50% share of the U.S. dialysis market. (P) (V)
MAGE
| Price | $59.39 |
| Price change for today in $ | +$1.98 |
| Price change for today in % | +3.45% |
| P&P rating | ![]() |
| Open Price | |
| Previous close | $57.41 |
| Daily Range | $56.75 - $59.75 |
| 52-Week Range | $47.09 - $63.47 |
| Volume | 4,606,280 |



Year over year earnings are down. Sales are flat. ROE is mediocre.
Overvalued relative to its peers.
By the middle of next year, there will be some kick and upside to this stock.
But for now, there are better places to make money.
Comments: 0 | Comment
The survival and cardiovascular benefits of phosphate binders Renagel and Renvela are bolstering sales, and Genzyme recently claimed more than a 50% share of the U.S. dialysis market. (P) (V)
MAGE
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 1 | Comment
Comments: 1 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment
Comments: 0 | Comment